CERo Therapeutics

(NASDAQ) CERO

Current PriceN/A

Market CapN/A

Since IPO (2021)-100%

5 YearN/A

1 Year-100%

1 Month-37%

CERo Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$20.70M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 2, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 2, 2026

CERO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CERo Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Christopher B. Ehrlich, MBA

Website

www.cero.bio

Headquarters

South San Francisco, CA 94080, US

CERO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

396.51%

Return on Capital

N/A

Return on Assets

-938.74%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$1.09M

Operating Income

-$18.36M

EBITDA

-$17.97M

Operating Cash Flow

-$14.40M

Capital Expenditure

-$5.00

Free Cash Flow

-$14.40M

Cash & ST Invst.

$857.49K

Total Debt

$598.35K

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$276.14K

-2.5%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$5.89M

-15.3%

EBITDA

-$4.57M

+5.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$857.49K

-83.5%

Total Debt

$598.35K

-56.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$136.77K

-70.4%

Short Term Debt

$461.58K

-74.5%

Return on Assets

-9.39%

N/A

Return on Invested Capital

2.01%

N/A

Free Cash Flow

-$2.76M

+37.9%

Operating Cash Flow

-$2.76M

+37.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LIMNLiminatus Pharma, Inc. Class A Common Stock

LIMNLiminatus Pharma, Inc. Class A Common Stock$0.11+1.70%

XRTXXORTX Therapeutics Inc.

XRTXXORTX Therapeutics Inc.$2.20+0.46%

GLMDGalmed Pharmaceuticals Ltd.

GLMDGalmed Pharmaceuticals Ltd.$0.57-0.45%

NKGNNKGen Biotech, Inc. Common Stock

NKGNNKGen Biotech, Inc. Common Stock$0.06+0.00%

BIVIBioVie Inc.

BIVIBioVie Inc.$2.01+3.61%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$1.21+6.14%

BCTXZBriaCell Therapeutics Corp. Warrant

BCTXZBriaCell Therapeutics Corp. Warrant$0.08+3.23%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CMCSAComcast

CMCSAComcast$24.22+0.05%

TAT&T

TAT&T$21.82-0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.64+0.17%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.19+0.07%

SOFISoFi Technologies

SOFISoFi Technologies$18.19+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.16-0.08%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.49-0.03%

Questions About CERO

What is the current price of CERo Therapeutics?

CERo Therapeutics is trading at N/A per share.

What is the 52-week range for CERo Therapeutics?

Over the past 52 weeks, CERo Therapeutics has traded between N/A and N/A.

How much debt does CERo Therapeutics have?

As of the most recent reporting period, CERo Therapeutics reported total debt of $598.35K.

How much cash does CERo Therapeutics have on hand?

CERo Therapeutics reported $857.49K in cash and cash equivalents in its most recent financial results.

What is CERo Therapeutics’s dividend yield?

CERo Therapeutics does not currently have a dividend yield.

CERo Therapeutics

CERo Therapeutics Financials at a Glance

CERO News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About CERo Therapeutics

CERO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CERO

What is the current price of CERo Therapeutics?

What is the 52-week range for CERo Therapeutics?

How much debt does CERo Therapeutics have?

How much cash does CERo Therapeutics have on hand?

What is CERo Therapeutics’s dividend yield?

Premium Investing Services